Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 for seasonal allergic rhinitis
CTR20250476Phase 3Completed
- Sponsor
- Medigene AG
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of comekibart in seasonal allergic rhinitis (SAR), sponsored by Medigene AG. Started Feb 2025; status: completed.
02
Drugs
comekibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20250476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250476.